Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been hindered by the propensity of the virus to evade host immune responses. HCV particles in serum and in cell culture associate with lipoproteins, which contribute to viral entry. Lipoprotein association has also been proposed to mediate viral evasion of the humoral immune response, though the mechanisms are poorly defined. METHODS: We used small interfering RNAs to reduce levels of apolipoprotein E (apoE) in cell cultureÀderived HCVÀproducing Huh7.5-derived hepatoma cells and confirmed its depletion by immunoblot analyses of purified viral particles. Before infection of naïve hepatoma cells, we exposed cell cultureÀderived HCV strains of different genotypes, subtypes, and variants to serum and polyclonal and monoclonal antibodies isolated from patients with chronic HCV infection. We analyzed the interaction of apoE with viral envelope glycoprotein 2 and HCV virions by immunoprecipitation. RESULTS: Through loss-of-function studies on patient-derived HCV variants of several genotypes and subtypes, we found that the HCV particle apoE allows the virus to avoid neutralization by patient-derived antibodies. Functional studies with human monoclonal antiviral antibodies showed that conformational epitopes of envelope glycoprotein 2 domains B and C were exposed after depletion of apoE. The level and conformation of virion-associated apoE affected the ability of the virus to escape neutralization by antibodies. CONCLUSIONS: In cell-infection studies, we found that HCV-associated apoE helps the virus avoid neutralization by antibodies against HCV isolated from chronically infected patients. This method of immune evasion poses a challenge for the development of HCV vaccines.
BACKGROUND & AIMS:
Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been hindered by the propensity of the virus to evade host immune responses. HCV particles in serum and in cell culture associate with lipoproteins, which contribute to viral entry. Lipoprotein association has also been proposed to mediate viral evasion of the humoral immune response, though the mechanisms are poorly defined. METHODS: We used small interfering RNAs to reduce levels of apolipoprotein E (apoE) in cell cultureÀderived HCVÀproducing Huh7.5-derived hepatoma cells and confirmed its depletion by immunoblot analyses of purified viral particles. Before infection of naïve hepatoma cells, we exposed cell cultureÀderived HCV strains of different genotypes, subtypes, and variants to serum and polyclonal and monoclonal antibodies isolated from patients with chronic HCV infection. We analyzed the interaction of apoE with viral envelope glycoprotein 2 and HCV virions by immunoprecipitation. RESULTS: Through loss-of-function studies on patient-derived HCV variants of several genotypes and subtypes, we found that the HCV particle apoE allows the virus to avoid neutralization by patient-derived antibodies. Functional studies with human monoclonal antiviral antibodies showed that conformational epitopes of envelope glycoprotein 2 domains B and C were exposed after depletion of apoE. The level and conformation of virion-associated apoE affected the ability of the virus to escape neutralization by antibodies. CONCLUSIONS: In cell-infection studies, we found that HCV-associated apoE helps the virus avoid neutralization by antibodies against HCV isolated from chronically infected patients. This method of immune evasion poses a challenge for the development of HCV vaccines.
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H epatitis C virus (HCV) is a major health problem infecting approximately 130 million individuals worldwide. HCV infection typically results in a chronic
infection that can lead to liver cirrhosis and hepatocellular carcinoma. 1 Direct-acting antivirals have markedly improved the treatment efficacy, but limitations due to access to screening and therapy persist, highlighting the need for an effective vaccine for global control and eradication of HCV infection. A consistent hallmark of vaccines against pathogens is their reliance on immunogens that elicit neutralizing antibodies (nAbs). 2 HCV vaccine development has been impeded by the viral adaptations to host immunity that enable chronic infection. Indeed, the host immune system lags behind the continuous evolution of HCV, allowing the virus to evade humoral immunity. 3, 4 However, the escape mechanisms from nAbs during chronic HCV infection are only partially understood. Clearly, the development of an effective vaccine requires a detailed understanding of viral evasion from host immune responses, including nAbs. Previous studies investigating the molecular mechanisms of HCV liver graft infection, identified a viral variant termed VL 5, 6 with efficient escape from patient nAbs. 5, 6 Functional genetics had identified phenylalanine at HCV polyprotein residue 447 as being important for neutralization escape. 6 This amino acid is widely conserved among HCV isolates, as shown by its prevalence of 98.4% in all genotypes (including Jc1, Japanese fulminant hepatitis virus [JFH1], and H77) and 96.2% in genotype 1b strains (including VL). 6 In addition, previous studies had shown that replacement of phenylalanine by leucine (F447L) rendered HCV highly susceptible to neutralization.
An interesting characteristic of HCV particles is their association with triglyceride-rich lipoproteins (TRL) and low-density lipoproteins (LDL) forming hybrid lipoviral particles, which results in a population of virions that are heterogenous in buoyant density. [7] [8] [9] Apolipoprotein (apo) B, E, AI, and CI have been described as lipoviral particles components. 10 ApoE is important for both HCV infection of hepatocytes and hepatic uptake of TRL remnants, while the role of apoB, the structural protein of TRL and LDL, in the HCV life cycle is less clear. ApoCI may be involved in viral fusion, 11 and apoAI can affect HCV replication and production. Although association with TRL and LDL has been hypothesized to contribute to viral evasion, 7, 12 the role of specific apolipoproteins in HCV persistence is unknown. Given that apoE is a host protein incorporated into the HCV particle and is required for virion production, we sought to determine its functional role in viral evasion from host nAbs. Our findings reveal a previously undiscovered mechanism of viral escape specific to apoE, independent of TRL binding, and identify a residue in envelope glycoprotein 2 (E2) that contributes to this phenotype. These results define a novel challenge for the development of vaccines and immunopreventive approaches.
Materials and Methods

Patient Samples
Serum samples from patients with chronic HCV infection were obtained with informed consent and approval from the Strasbourg University Hospital's Institutional Review Board (CPP 10-17). Sera termed 1, 2, and 4 came from patients Figure 1 . Depletion of apoE in HCV producer cells efficiently sensitizes HCV virions to antibody-mediated neutralization.
Huh7.5.1 cells were either electroporated with VL:JFH1 (A), H77R2a (B) or Luc-Jc1 RNA (C) alone, or coelectroporated with either scrambled siRNA (siCtrl) or siRNA targeting apoE mRNA (siApoE). Neutralization experiments using viruses produced from these cells were performed using sera from 4 different HCV-infected patients (1, 2, 3, or 4) at the indicated dilutions.
Infection was determined by end-point dilution assay (A) or luciferase activity (B, C). Mean ± SEM from 7 experiments (A) or 3 experiments performed in duplicate (B, C) are shown.
Results are expressed as fold increase of neutralization relative to control serum. ApoE depletion in producer cells was confirmed 72 hours post electroporation by immunoblotting of cell lysates; actin was detected as loading control. *P < .05. Q19 infected by HCV genotype 1 and serum 3 from a genotype 2 patient.
Cells and Reagents
Huh7.5.1 and Huh7.5 green fluorescent protein cells were cultured as described previously. 13 Silencing
Q6
RNAs (siRNAs) targeting apoE 3 0 untranslated region (siApoE) (5 0 CUGCAGCGGGAGACCCUGU 3 0 ) or apoB and control siRNAs were from Dharmacon (Lafayette, CO). Mouse anti-apoE (ab8226) monoclonal antibody (mAb) and antiÀb-actin (ab1906) for immunoblot were obtained from Abcam (Cambridge, MA). Mouse anti-apoE (1D7, 3H1, 6C5), rat anti-CD81 (QV-6A8-F2-C4), mouse anti-E2 (AP33), [14] [15] [16] and human anti-E2 (CBH-23 and HC-1) 17 mAbs have been described. Sheep anti-NS5A serum was a kind gift from M. Harris. 18 Human anti-E2 antibody AR3B was a kind gift from M. Law. 19 Antibodies and peptides for FLAG purification and detection were obtained from Sigma-Aldrich (St Louis, MO). Purification of IgG from patient serum was performed using MAbTrap kit from Amersham (Little Chalfont, UK).
Cell CultureÀDerived Hepatitis C Virus Production, Infection, and Neutralization Plasmids for cell cultureÀderived HCV (HCVcc) production of Jc1, J6-JFH1 chimera with luciferase reporter (Luc-Jc1), Jc1E2FLAG (all genotype 2a/2a), H77R2a (genotype 1a/2a), Figure 2 . (A) Trans-complementation of apoE expression in producer cells restores viral evasion from nAbs. Huh7.5.1 cells were electroporated with Luc-Jc1 RNA alone, or co-electroporated with either scrambled siRNA (siCtrl) or siRNA targeting apoE mRNA (siApoE). ApoE expression was then rescued using adenoviral apoE expression vectors transducing apoE knockdown cells. Neutralization experiments of viruses were performed using HCV-infected patient serum 1 at dilution 1/200. Infection was determined by quantification of luciferase activity. Results are expressed as fold increase of neutralization relative to control serum. ApoE knockdown was confirmed 72 hours post electroporation by immunoblotting (lower panel); actin was detected as loading control. Mean ± SEM from 3 experiments are shown. *P < .01. (B, C) ApoE-depletion results in enhanced neutralization by purified IgG from patient sera and human monoclonal antibodies. Huh7.5.1 cells were electroporated with Luc-Jc1 RNA alone, or co-electroporated with either scrambled siRNA (siCtrl) or siRNA targeting apoE mRNA (siApoE). Viruses produced from these cells were incubated with (B) purified IgG (25 mg/mL) from HCV-infected patient serum 2 and 3 or (C) human monoclonal anti-E2 antibodies CBH-23 and HC-1 (10 mg/mL). Infection was determined as described in (A). Results are expressed as fold increase of neutralization relative to control IgG. Mean ± SEM from 3 experiments are shown. *P < .01. VL:JFH1, and VL:JFH1FLAG (genotype 1b/2a) have been described previously. 6, 9, [20] [21] [22] HCVcc were produced in Huh7.5.1 as described previously. 20 Infectivity was quantified by luciferase activity or tissue culture infectious dose 50% using anti-NS5A antibody. 23 HCVcc neutralization using patient serum, IgG, and mAbs was analyzed as described previously. 6 
Silencing of Apolipoproteins in Hepatitis C Virus Producer Cells
Silencing of apoE and apoB expression and immunoblotting in Huh7.5.1 cells were performed as described previously. (siCtrl) or siRNA targeting apoE messenger RNA (mRNA) (siApoE) or apoB mRNA (siApoB) according to the manufacturer's instructions. Supernatants and cells were harvested 72 hours post electroporation. Protein expression was analyzed by immunoblotting as described previously. 24 
Recombinant Adenoviruses and Rescue of Gene Silencing
The recombinant adenoviral genomes were generated as described previously. 25 Recombinant adenoviruses Ad-apoE were generated by transfection of these plasmids into the 293T packaging cell line after PacI digestion.
25 Huh7.5.1 cells were electroporated with HCV RNA and siApoE or a scramble siRNA (siCtrl). Twenty-four hours post electroporation, cells were transduced with adenoviruses expressing apoE. After 72 hours, viruses were harvested and tested in neutralization experiments and both silencing and rescue of protein expression was confirmed by immunoblotting.
Generation and Purification of E2-FLAG Tagged Viruses
The VL:JFH1 derivatives encoding a E2(FLAG) fusion protein were generated using overlap polymerase chain reaction (PCR) with 2 sets of primers: S_E1_AgeI_Con1 (5 0 ATAGTGGTCTGCGGAACCGGT3 0 ) and A_E1_FLAG (5 0 CCCTT GTCATCGTCGTCCTTGTAGTCCCCGTCAACGCCGGCAAAA3 0 ); S_E1 _FLAG (5 0 GGACGACGATGACAAGGGATCAGGAGCATCCACCTACA CGACGGGGGG3 0 ); and A_E2_AleI (5 0 TGTATGGATAGTCAACCAT3 0 ). Amplicons were amplified by PCR from VL:JFH1 derivates (VL:JFH1 or F447L or F447A), then combined by overlap PCR using S_E1_AgeI_Con1 and A_E2_AleI before insertion of the resulting fragments into the VL:JFH1 construct. E2(FLAG) encoding HCV viruses were purified using anti-FLAG M2 affinity gel, as described previously. 9 Virion-associated apoE was detected by immunoblotting using mouse anti-apoE mAb (ab8226; Abcam), while virion E2(FLAG) was detected by anti-FLAG M2 mAb (Sigma-Aldrich). Quantification of apoE, E2(FLAG), and actin protein expression was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).
Quantification of Hepatitis C Virus Particle Buoyant Density Distribution
VL:JFH1 HCVcc virus was concentrated 10-fold using a Vivaspin column (GE Healthcare, Little Chalfont, UK). Density distributions of infectious HCVcc were determined by overlaying 0.5 mL culture media on a 5-mL, 4%À40% iodixanol step gradient, and ultracentrifuging samples for 16 hours at 40,000 rpm on a SW-55 rotor (Beckman Coulter, Brea, CA). Six hundred and twenty-five microliter fractions were carefully harvested from the top of each tube, and density was determined by weighing 0.5 mL of each fraction. Infectivity of each fraction was quantified by luciferase activity or by tissue culture infectious dose 50%. Figure 4 . Depletion of apoB in HCV producer cells has no effect on HCV neutralization. Huh7.5.1 cells were either electroporated with VL:JFH1 or Luc-Jc1 RNA alone, or co-electroporated with either scrambled siRNA (siCtrl) or siRNA targeting apoB mRNA (siApoB). Neutralization experiments on viruses produced from these cells were performed using patient serum 1 at the indicated dilutions. Infection was determined by (A) end-point dilution assay, and (B) quantification of luciferase activity. Results are expressed as fold increase of neutralization relative to control serum. ApoB knockdown was confirmed 72 hours post electroporation by immunoblotting (lower panel); actin was detected as loading control. Means ± SEM from 3 experiments are shown. 481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540   541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598 599 600
Hepatitis C Virus Cell-to-Cell Transmission HCV cell-to-cell transmission was assessed as described previously. 13 Producer Huh7.5.1 cells were electroporated with Jc1 RNA or VL:JFH1 RNA. Medium was exchanged 4 hours and again 24 hours post electroporation, and naïve target Huh7.5 green fluorescent protein cells were added concomitantly with mouse nAb AP33 (10 mg/mL) to block cell-free transmission. For analysis of the role of virus and host cell factors, cells were incubated with 10 mg/mL of either control IgG, anti-CD81 (QV-6A8-F2-C4), 14 or anti-apoE (1D7) 16 antibodies. Seventy-two hours post electroporation, cells were fixed with paraformaldehyde, stained with a human anti-E2 (AR3B) 19 antibody and analyzed via flow cytometry.
Immunoprecipitation, RNA Extraction, and Reverse Transcription Quantitative Polymerase Chain Reaction VL:JFH1 HCVcc virus was concentrated 10-fold from cell supernatants using a Vivaspin column (GE Healthcare) and immunoprecipitations were performed using Protein A/G PLUS-agarose beads according to the manufacturer instructions (Santa Cruz Biotechnology, Santa Cruz, CA). HCV RNA from immunoprecipitated viruses was isolated using RNeasy extraction (Qiagen, Valencia, CA) and quantified using reverse transcription quantitative PCR as described previously. 13, 24 E2-apoE co-immunoprecipitation using lysates of Huh7/ LunetCD81H cells stably expressing ApoE WT or ApoE HA and transfected with VL:JFH1 or the 447 mutant were performed as described elsewhere. 26 Immunoprecipitation of apoE from Huh7.5.1 cells was performed as described previously. 26 
Statistics
Datasets were analyzed using the MannÀWhitney test.
Results
Because apoE has been shown to be part of the HCV infectious virion mediating viral attachment, we investigated whether particle-associated apoE influences viral evasion from host nAbs. To experimentally probe this question, we used 3 different HCV strains comprising genotypes 1a, 1b, and 2a. We first studied HCV strain JFH1 carrying the structural genes of a patient-derived viral variant termed VL. We had previously shown that this genotype 1b variant is selected during liver graft infection due to envelope-mediated enhanced viral entry and broad escape from patient-derived Figure 5 . ApoE depletion in HCV producer cells does not modulate the buoyant density profile of virions. Huh7.5.1 cells were either electroporated with VL:JFH1 RNA or Luc-Jc1 alone (black squares and black circles, respectively), or co-electroporated with either scrambled siRNA (siCtrl) (dark gray squares and dark gray circles) or siRNA targeting apoE mRNA (siApoE) (light gray squares and light gray circles). HCVcc produced from these cells were fractionated using 4%À40% iodixanol density gradient ultracentrifugation. Each fraction was assayed for infectivity by (A) end-point dilution assay (log 10 tissue culture infectious dose 50%/mL) for VL:JFH1 or (B) quantification of luciferase activity (log 10 RLU) for Luc-Jc1. Mean ± SEM from 3 experiments are shown. The light gray circles on the density plot show the mean density for each fraction and the error bars indicate the SD of the density of the respective fraction from 6 independent experiments. ApoE knockdown was confirmed 72 hours postelectroporation by immunoblotting (lower panels); actin was detected as loading control.
autologous and heterologous nAbs. 5, 6 Thus, it represents a prototype variant that may be largely refractory to immunopreventive approaches or vaccines. We first generated VL:JFH1 HCVcc by cotransfecting HCV RNA alone, with a scrambled nucleotide control (siCtrl), or with siRNA that targets apoE expression (siApoE). Similar to the range reported previously, 24, 27, 28 silencing of apoE expression in Huh7.5.1 producer cells resulted in a marked (50%À70%) and significant decrease (P < .001) in infectivity of viruses relative to viruses with unchanged apoE expression. Exposure of VL:JFH1 HCVcc produced from apoE-depleted cells to multiple patient sera with chronic HCV infection modified these HCVcc to be highly sensitive to nAbs ( Figure 1A) . Depending on the patient serum and the dilution used, viruses produced from apoE-depleted cells were 4-17 times more sensitive to neutralization by patient sera than viruses from control cells with unchanged apoE expression ( Figure 1A ). To corroborate these findings, we studied the phenotype of 2 additional variants, H77R2a 21 expressing the structural genes of the HCV strain H77 (genotype 1a) and J6:JFH1 prototype Luc-Jc1 29 expressing the structural genes of the genotype 2 HCV strain J6. Similar to findings obtained for VL:JFH1 viruses, apoE depletion resulted in enhanced sensitivity to neutralization by patient sera (Figure 1B and C) .
H77R2a and Luc-Jc1 viruses produced from apoE-depleted cells were 2 to 10 times and 1.5 to 2 times more sensitive to neutralization than control viruses, respectively ( Figure 1B and C). Luc-Jc1 derived from apoE-deficient cells were more sensitive to nAbs regardless of their viral infectivity titers (Supplementary Figure 1) . In addition, similar neutralization results were obtained upon adjustment of input virus titers between viruses produced from control and apoE-depleted cells (Supplementary Figure 2) , ruling out that altered sensitivity was due to a difference in molar ratios between nAbs and HCVcc.
To further explore the role of apoE in viral evasion, we next performed trans-complementation assays using adenoviral apoE expression vectors transducing apoE knockdown cells. Ectopic apoE expression restored the HCV nAb escape to the same level as HCV produced in control cells (Figure 2A) , excluding off-target effects caused by the siRNA. In addition, to determine that this observation was antibody mediated, we confirmed our results using IgG purified from sera of patients with chronic HCV infection ( Figure 2B ). Similar to the experiments with patient sera, we observed that Luc-Jc1 viruses produced from apoE-depleted cells were 2 times more sensitive to neutralization by purified IgG than control viruses. These findings specifically point to serum IgG and exclude other serum factors in determining the sensitivity of HCV from apoE-silenced cells ( Figure 2B ). In addition, we used 2 human mAbs targeting HCV E2 domain B (HC-1) or domain C (CBH-23) and tested their efficacy to neutralize viruses produced from control and apoE-silenced cells ( Figure 2C ). Consistent with the results obtained with patient sera and anti-HCV polyclonal IgG, we found that apoE silencing markedly (3-to 4-fold) and significantly (P < .01) increased sensitivity to neutralization compared with controls. These results clearly indicate that apoE plays a key role in mediating viral escape from nAbs and suggest that conformational epitopes of E2 domain B and domain C are exposed to nAbs after apoE depletion ( Figure 2C) .
To confirm the hypothesis that apoE modulation affected virion composition, we utilized J6-JFH1 chimera with FLAG epitope in E2 (Jc1E2[FLAG]) 9 and VL:JFH1E2(FLAG) HCVcc purified from nonassociated serum component contaminants.
Immune-purification of Jc1E2(FLAG) and VL:JFH1E2(FLAG) using an antibody targeting the FLAG-tag of the virion E2 revealed that silencing of cellular apoE resulted in an approximate 50% and 80% decrease of virion-E2 associated apoE for Jc1E2(FLAG) and VL:JFH1E2(FLAG) compared with controls, respectively (Figure 3) . Intracellular levels of apoE were decreased by 75% and 85%, respectively (Figure 3) . Furthermore, virions produced from apoE-depleted cells appeared to have a decreased inhibition of infection by anti-apoE antibodies (Supplementary Figure 3) . These findings highlight virionassociated apoE's critical role in mediating escape from nAbs.
To test if apoB, another component of HCV, plays a role similar to apoE's in mediating escape, we silenced apoB expression in HCV-producing cells. Silencing of either apolipoprotein had no detectable effect on the level of the other apoliprotein (Supplementary Figure 4) ensuring absence of the interfering effects of apoE/B silencing. Interestingly, while apoB knockdown was effective ( Figure 4A and B), it did not alter the production of VL:JFH1 and Luc-Jc1. Furthermore, neither VL:JFH1 nor Luc-Jc1 viruses produced from apoB-silenced cells were altered in sensitivity to nAbs ( Figure 4A and B) . These results point directly to apoE as a key apolipoprotein mediating nAb escape and do not support a major functional role of apoB in nAb evasion.
ApoE expression is an important regulator of HCV production, and a key component of TRLs. TRL association, measured by buoyant density distribution, could shield HCV glycoproteins from nAbs. 12 Two distinct models have been proposed regarding HCVÀapoE interaction and lipoviral particles formation: a 1-particle model presenting the virion inextricably fused to the lipoprotein with apoE on its surface, and a 2-particle model where HCV glycoproteins interact with apoE directly, which may mediate lipoprotein attachment. 30 In addition, the envelope glycoprotein, and the transmembrane domain of E2 specifically is critical for = -specific antibody and captured complexes were analyzed by immunoblotting using anti-E2 antibodies. To determine capture efficiency, 0.5% of total cell lysates used for immunoprecipiation were analyzed in parallel (input). One representative immunoblot is shown. (E) ApoE and E2 associations in purified virions of wild-type and mutant viruses. Virions were immunopurified from supernatants of HCV producer cells using an anti-FLAG antibody. Virion-associated proteins were analyzed by immunoblots using FLAG and apoEspecific antibodies. Results of 2 independent purifications and immunoblots are shown. apoE association. 26, 31 If apoE protects HCV glycoproteins from nAbs directly, then our observations regarding the nAb-sensitivity of HCV generated from apoE knockdown cells will not be mediated by a marked difference in buoyant density distribution. To test this hypothesis, we analyzed the buoyant density distribution of infectious particles using isopycnic density gradient ultracentrifugation. Interestingly, the density distribution of VL:JFH1 and Luc-Jc1 was unaltered after apoE knockdown, though infectivity was diminished approximately equally in each density fraction in both VL:JFH1 and Luc-Jc1 viruses ( Figure 5A and B) . These data suggest that apoE knockdown does not modulate HCV-TRL association, and apoE directly associated with the virion accounts for nAb evasion.
Cell-to-cell transmission is another mechanism to avoid nAbs. 32 To investigate whether apoE association is relevant in cell-to-cell transmission, we used an anti-apoE antibody (1D7) that binds the low-density lipoprotein receptorÀbinding domain of apoE 16 and inhibits HCV infection ( Figure 7A ). Jc1 demonstrated an approximately 3-fold higher capacity to spread by direct cell-to-cell transmission than VL:JFH1 in this assay ( Figure 6A ). While 1D7 did not affect cell-to-cell spread, despite its capacity to strongly inhibit extracellular transmission, antibodies recognizing HCV entry factor CD81 14 inhibited 70%À80% of cell-to-cell transmission of both Jc1 and VL:JFH1 ( Figure 6A , B, and C). These data indicate that cell-cell transmission is not mediated by apoE domains targeted by anti-apoE antibody 1D7.
Recently, 2 studies demonstrated that apoE interacts with HCV E2. 26, 31 To define E2 domains relevant for association with apoE and neutralization escape, we took advantage of a mutation identified in variant A (VA), a pretransplant variant that was selected against in the same transplant recipient that contained the predominant VL variant. 6 Indeed, replacing phenylalanine with the leucine encoded in VA rendered the virus both sensitive to neutralization and less dependent on CD81 for cell entry. 6 To determine whether this residue is involved in the differential utilization of apoE, we used the previously described mutant restoring neutralization escape (F447L), as well as an additional mutant where phenylalanine is replaced by alanine (F447A), a smaller amino acid residue than leucine. Interestingly, the wild-type VL:JFH1 escape variant was efficiently neutralized by anti-apoE 1D7, while the 447L and 447A mutants were at least 3-fold less sensitive to neutralization by this antibody, indicating that the wild-type virus is more dependent on apoE for infection ( Figure 7A ). In contrast, 2 other apoE-specific antibodies (3H1 and 6C5) that bind the N-and C-terminal regions of apoE, respectively, 16 did not inhibit HCV infection to the same degree (data not shown) despite their capacity to immunoprecipitate apoE from cell lysates (Supplementary Figure 5) . To determine if this modulation might be due to altered apoE association with virus particles, we immunoprecipitated VL:JFH1 with either nonspecific mouse IgG or with each of the three apoE-specific antibodies 1D7, 3H1, or 6C5. 16 Interestingly, all 3 anti-apoE antibodies were at least 2.5-fold more efficient at precipitating the VL:JFH1 than the 447 mutants ( Figure 7B ), suggesting a more robust association of the escape variant with apoE or a different E2-apoE conformation with different exposure of these epitopes on this variant. The functional relevance of apoE for immunoprecipitation of virions was confirmed by less efficient immunoprecipitation of HCV RNA by anti-apoE using VL:JFH1 and Jc1 viruses produced in apoE-depleted cells ( Figure 7C and data not shown) .
To investigate whether the difference in sensitivity and pull-down of VL:JFH1 447 mutants by anti-apoE antibodies was due to an altered association of apoE and virion E2 or mediated by a different conformation of the apoE-E2 complex, we performed co-immunoprecipitation analyses in cell lysates of HCV producer cells. We observed similar intracellular apoE-E2 binding in wild-type and mutant viruses ( Figure 7D ). Next, we determined the amount of apoE incorporated into virions by using immunopurified E2 FLAG -tagged viruses. We found that FLAG-tagged wild-type and F447L mutant viruses contained similar levels of apoE ( Figure 7E ). These data indicate that residue 447 alters the conformation of the virion E2-apoE complex without changing apoE content of the particles. Collectively, our data indicate that both the level (Figures 1-3) , as well as the conformation (Figure 7 ) of virion apoE are relevant for the evasion from nAbs.
Discussion
Here we present experimental evidence indicating that apoE levels in HCV-producing cells determine HCV's capacity to avoid the effect of nAbs through modifying incorporation of apoE into the viral particle. These results were obtained using structural genes from 3 different viral strains from genotypes 1a, 1b, and 2a, sera from multiple patients as well as patient-derived purified IgG and mAbs, indicating that utilization of the host factor apoE as a mechanism to escape from nAbs is pan-genotypic. While the utilization of apoE is consistently employed, it was most prominently observed in both genotype 1 variants H77 and VL, a clinically derived variant previously characterized as effective at nAb escape, highlighting that apoE "shielding" may be employed by the most difficult to neutralize variants. These differences of neutralization profiles between H77 or VL:JFH1 and Jc1 may be partially explained by a more efficient depletion of apoE in VL:JFH1 compared to Jc1 as shown in Figure 3 . Alternatively, these results may point to genotype-or isolate-dependent differences in utilization of apoE and neutralization escape. Finally, the differences may be due to different cross-reactivity of the patient sera used.
We further confirmed the role of apoE through observing altered apoE:E2 ratios on purified virions after silencing ( Figure 3 ) and trans-complementing apoE expression after knockdown, which rescued HCV's capacity to avoid inhibition of HCV entry by nAbs present in serum of chronically infected patients (Figure 2A) . However, downregulation of apoE expression did not affect HCV-TRL association ( Figure 5 ), indicating that the apoE-mediated mechanism of nAb escape is distinct from the previously described role of TRL in escape.
Using an anti-apoE antibody that blocks extracellular transmission, we did not detect a role of apoE in cell-to-cell transmission of Jc1, VL:JFH1, as well as the 2 VL:JFH1 variants (Supplementary Figure 6) . This is consistent with the report from Barretto et al. 33 Engineering nonhepatic cells to produce HCV through ectopic apoE expression can confer cell-to-cell transmission capacity, albeit to a limited degree relative to the levels observed in the current study. 34 We thus cannot exclude that epitopes not recognized by the utilized anti-apoE antibody play a role in cell-to-cell transmission or that this antibody may have limited access to the virus during this process.
In variants that were selected during liver transplantation, replacement of phenylalanine at E2 residue 447 appeared to alter the immunoprecipitation of virions by anti-apoE antibodies ( Figure 7B) . Given the comparable level of intracellular E2-apoE association ( Figure 7D ) and apoE incorporation into virions ( Figure 7E ) of the wild-type and the mutant, mutations of E2 residue 447 appear to induce conformational changes in the E2-apoE complex affecting the sensitivity to neutralization by both apoE-and E2-specific nAbs (Figures 1, 2, and 7) . Collectively our data indicate that virion apoE levels (Figures 1-3 ) and conformation ( Figure 7) are relevant for the evasion from nAbs.
ApoE plays a key role in viral attachment to heparan sulfate proteoglycans, 25, 35 whereas subsequent steps of viral entry require E2-SR-BI and E2-CD81 interactions (reviewed in Zeisel et al. 36 ). Thus, dissociation of apoE and/ or alteration of the apoE-E2 complex might be required for envelope-SR-BI and CD81 interactions occurring post binding. Supporting this model, our results demonstrate that conformational human mAbs CBH-23 and HC-1, which impair HCV entry by interfering with E2ÀCD81 interactions and act at a post-binding step, 6 more effectively neutralize apoE-depleted HCV.
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Supplementary Material
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Supplementary Figure 3 . Inhibition of viruses produced from apoE silenced producer cells by anti-apoE or anti-CD81 antibodies. Huh7.5.1 cells were electroporated with VL:JFH1 alone, or co-electroporated with either scrambled siRNA (siCtrl) or siRNA targeting apoE mRNA (siApoE). To assess the role of CD81, cells were pretreated with 10 mg/mL anti-CD81 antibody for 30 minutes before HCVcc infection of Huh7.5.1 cells. To assess the role of apoE, HCVcc were preincubated with 10 mg/mL anti-apoE antibody (1D7) for 1 hour before infection of Huh7.5.1 cells. Infection was determined by end-point dilution assay and expressed as percentage of infection relative to control antibodies. Mean ± SEM from 4 independent experiments are shown. P < .05.
Supplementary Figure 4 . Silencing of apoE expression in HCV producer cells has no effect on apoB expression and vice versa. Huh7.5.1 cells were electroporated with Luc-Jc1 RNA alone, or co-electroporated with either scrambled siRNA (siCtrl) or siRNA targeting either apoE mRNA (siApoE) or apoB mRNA (siApoB). After 72 hours, apoB and apoE expression was quantified using immunoblots of cell lysates and anti-apoE and apoB specific antibodies; actin expression was analyzed as control. A representative immunoblot is shown. 1801  1802  1803  1804  1805  1806  1807  1808  1809  1810  1811  1812  1813  1814  1815  1816  1817  1818  1819  1820  1821  1822  1823  1824  1825  1826  1827  1828  1829  1830  1831  1832  1833  1834  1835  1836  1837  1838  1839  1840  1841  1842  1843  1844  1845  1846  1847  1848  1849  1850  1851  1852  1853  1854  1855  1856  1857  1858  1859  1860   1861  1862  1863  1864  1865  1866  1867  1868  1869  1870  1871  1872  1873  1874  1875  1876  1877  1878  1879  1880  1881  1882  1883  1884  1885  1886  1887  1888  1889  1890  1891  1892  1893  1894  1895  1896  1897  1898  1899  1900  1901  1902  1903  1904  1905  1906  1907  1908  1909  1910  1911  1912  1913  1914  1915  1916  1917  1918 Supplementary Figure 5 . Immunoprecipitation of apoE using anti-apoE antibodies 1D7, 3H1 and 6C5 in Huh7.5.1 cell lysates. ApoE was immunoprecipitated from cell lysates as described in Materials and Methods and apoE on immunoprecipitated beads was subjected to immunoblot using antiapoE antibody (Abcam). Isotype IgG served as negative control for immunoprecipitation. Two independent experiments have been performed. A representative immunoblot is shown.
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